Quantitative proteomic analysis of the metastasis-inhibitory mechanism of miR-193a-3p in non-small cell lung cancer

Cellular Physiology and Biochemistry

Volumn 35, Issue 5, 2015, Pages 1677-1688

  Deng, Wei ^a   Yan, Mingxia ^a   Yu, Tao ^a   Ge, Haiyan ^b   Lin, Hechun ^a   Li, Jing ^a   Liu, Ying ^a   Geng, Qin ^a   Zhu, Miaoxin ^a   Liu, Lei ^a   He, Xianghuo ^a   Yao, Ming ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Propaganda Department   (China)

Author keywords

iTRAQ; MiR 193a 3p; NSCLC; Proteome

Indexed keywords

MICRORNA; MICRORNA 193A 3P; UNCLASSIFIED DRUG; ANTISENSE OLIGONUCLEOTIDE; MIRN193 MICRORNA, HUMAN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOINFORMATICS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; RNA TRANSPORT; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CLUSTER ANALYSIS; FACTUAL DATABASE; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; METASTASIS; PATHOLOGY; PROTEIN PROTEIN INTERACTION; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLUSTER ANALYSIS; DATABASES, FACTUAL; DOWN-REGULATION; HUMANS; MICRORNAS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN INTERACTION MAPS; PROTEOMICS; TANDEM MASS SPECTROMETRY; UP-REGULATION;

EID: 84926211657     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000373981     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin 2012;5:283-298.
2. Crino L, Weder W, van Meerbeeck J, Felip E, Group EGW: Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:v103-115.
3. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;1:57-70.
4. Gdowicz-Klosok A, Giglok M, Drosik A, Suwinski R, Butkiewicz D: The SIPA1 -313A>G polymorphism is associated with prognosis in inoperable non-small cell lung cancer. Tumor Biol DOI 10.1007/s13277-014-2753-8.
5. Jia D, Yan M, Wang X, Hao X, Liang L, Liu L, Kong H, He X, Li J, Yao M: Development of a highly metastatic model that reveals a crucial role of fibronectin in lung cancer cell migration and invasion. BMC Cancer 2010;10:364.
6. Liang S, Xu Z, Xu X, Zhao X, Huang C, Wei Y: Quantitative proteomics for cancer biomarker discovery. Comb Chem High T Scr 2012;3:221-231.
7. Nikolov M, Schmidt C, Urlaub H: Quantitative mass spectrometry-based proteomics: an overview. Methods Mol Biol 2012;893:85-100.
8. Masui O, White NM, DeSouza LV, Krakovska O, Matta A, Metias S, Khalil B, Romaschin AD, Honey RJ, Stewart R, Pace K, Bjarnason GA, Siu KW, Yousef GM: Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Mol Cell Protemics 2013;1:132-144.
9. Jeppesen DK, Nawrocki A, Jensen SG, Thorsen K, Whitehead B, Howard KA, Dyrskjot L, Orntoft TF, Larsen MR, Ostenfeld MS: Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors. Proteomics 2014;6:699-712.
10. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 2009;2:215-233.
11. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N: Widespread changes in protein synthesis induced by microRNAs. Nature 2008;7209:58-63.
12. Calin GA, Croce CM: MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006;15:7390-7394.
13. Ambros V: The functions of animal microRNAs. Nature 2004;7006:350-355.
14. Shkumatava A, Stark A, Sive H, Bartel DP: Coherent but overlapping expression of microRNAs and their targets during vertebrate development. Gene Dev 2009;4:466-481.
15. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP: MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007;1:91-105.
16. Chi SW, Zang JB, Mele A, Darnell RB: Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 2009;7254:479-486.
17. Ritchie W, Flamant S, Rasko JE: Predicting microRNA targets and functions: traps for the unwary. Nat Methods 2009;6:397-398.
18. Thomson DW, Bracken CP, Goodall GJ: Experimental strategies for microRNA target identification. Nucleic Acids Res 2011;16:6845-6853.
19. Yu T, Li J, Yan M, Liu L, Lin H, Zhao F, Sun L, Zhang Y, Cui Y, Zhang F, Li J, He X, Yao M: MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogene DOI: 10.1038/onc.2013.574.
20. Baig RM, Mahjabeen I, Sabir M, Masood N, Ali K, Malik FA, Kayani MA: Mutational spectrum of Gelsolin and its down regulation is associated with breast cancer. Dis Markers 2013;2:71-80.
21. Shieh DB, Chen IW, Wei TY, Shao CY, Chang HJ, Chung CH, Wong TY, Jin YT: Tissue expression of gelsolin in oral carcinogenesis progression and its clinicopathological implications. Oral Oncol 2006;6:599-606.
22. Noske A, Denkert C, Schober H, Sers C, Zhumabayeva B, Weichert W, Dietel M, Wiechen K: Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer 2005;3:461-469.
23. Kim JH, Choi YK, Kwon HJ, Yang HK, Choi JH, Kim DY: Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J Gastroen Hepatol 2004;2:218-224.
24. Gay F, Estornes Y, Saurin JC, Joly-Pharaboz MO, Friederich E, Scoazec JY, Abello J: In colon carcinogenesis, the cytoskeletal protein gelsolin is down-regulated during the transition from adenoma to carcinoma. Hum Pathol 2008;10:1420-1430.
25. Cheng Y, Liu W, Kim ST, Sun J, Lu L, Sun J, Zheng SL, Isaacs WB, Xu J: Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study. Cancer Genet-NY 2011;7:375-381.
26. Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, Konopleva M, Andreeff M, Kornblau SM: Low expression of PP2A regulatory subunit B55alpha is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia 2011;11:1711-1717.
27. Liu W, Xie CC, Zhu Y, Li T, Sun J, Cheng Y, Ewing CM, Dalrymple S, Turner AR, Sun J, Isaacs JT, Chang BL, Zheng SL, Isaacs WB, Xu J: Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia 2008;8:897-907.
28. Shen S, Yue H, Li Y, Qin J, Li K, Liu Y, Wang J: Upregulation of miR-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targeting PPP2R2A. Tumor Biol 2014;1:631-640.
29. Jenkins Y, Markovtsov V, Lang W, Sharma P, Pearsall D, Warner J, Franci C, Huang B, Huang J, Yam GC, Vistan JP, Pali E, Vialard J, Janicot M, Lorens JB, Payan DG, Hitoshi Y: Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell 2005;12:5621-5629.
30. Unoki M, Nishidate T, Nakamura Y: ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 2004;46:7601-7610.
31. Daskalos A, Oleksiewicz U, Filia A, Nikolaidis G, Xinarianos G, Gosney JR, Malliri A, Field JK, Liloglou T: UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer. Cancer 2011;5:1027-1037.
32. Li X-L: Exogenous expression of UHRF1 promotes proliferation and metastasis of breast cancer cells. Oncol Rep 2012;28:375-83.
33. Wang F, Yang YZ, Shi CZ, Zhang P, Moyer MP, Zhang HZ, Zou Y, Qin HL: UHRF1 promotes cell growth and metastasis through repression of p16(ink(4)a) in colorectal cancer. Ann Surg Oncol 2012;8:2753-2762.
34. French J, Stirling R, Walsh M, Kennedy HD: The expression of Ras-GTPase activating protein SH3 domain-binding proteins, G3BPs, in human breast cancers. Histochemical J 2002;5:223-231.
35. Zhang HZ, Liu JG, Wei YP, Wu C, Cao YK, Wang M: Expression of G3BP and RhoC in esophageal squamous carcinoma and their effect on prognosis. World J Gastroentero 2007;30:4126-4130.
36. Zhang H, Zhang SH, He HW, Zhang CX, Yu DK, Shao RG: Downregulation of G3BPs inhibits the growth, migration and invasion of human lung carcinoma H1299 cells by suppressing the Src/FAK-associated signaling pathway. Cancer Gene Ther 2013;11:622-629.
37. Yang SH, Chang SY, Yin L, Tu Y, Hu Y, Yoshinaga Y, de Jong PJ, Fong LG, Young SG: An absence of both lamin B1 and lamin B2 in keratinocytes has no effect on cell proliferation or the development of skin and hair. Hum Mol Genet 2011;18:3537-3544.
38. Spraggon L, Dudnakova T, Slight J, Lustig-Yariv O, Cotterell J, Hastie N, Miles C: hnRNP-U directly interacts with WT1 and modulates WT1 transcriptional activation. Oncogene 2007;10:1484-1491.